|
|
 |
|
Viewing report
|
|
|
|
MRSA Drug Futures
Espicom Business Intelligence Ltd, Sep 2010, Pages: 108
MRSA: a complex issue
MRSA infection - especially the hospital acquired variety - has been front page news for some years, but reports of falling rates of infection in the US and Europe masks the real situation as far as drug treatments are concerned. Changes to clinical practice and attitudes to hygiene have played a significant part in reducing the incidence of MRSA. There remains the unresolved, but improving issue of the inappropriate over prescription of antibiotics and the resulting growth in resistance to many front line therapies. Despite progress, the fact remains that the arsenal of drugs available to treat MRSA remains limited.
Current therapies and future approaches:
It’s not all bad news. A number of drugs with different mechanisms of action have been approved for the treatment of infections caused by MRSA and there is a mixture of antibiotic classes in development for MRSA, including older ones, such as glycopeptides, modified versions of older classes, such as neoglycosides, and combinations, such as heterodimers (betalactam+glycopeptide).
The problem of ever-evolving resistance remains, and it is only a matter of time before the resourceful bacteria evolve once again to become resistant to novel antibiotic classes. It is in this regard that perhaps immunotherapies and vaccines may be the real key to success against MRSA.
The future MRSA landscape:
Three new products expected to launch from 2011 will add US$1.1 billion to the sector’s value taking the total MRSA market to in excess of US$4.1 billion. Pfizer will continue to dominate but its percentage share will diminish: declining revenues from Zyvox will be offset by increasing sales of Tygacil which will result in a small decline in overall revenues. At the same time Cubist Pharmaceuticals’ Cubicin and LEO Pharma’s Fucidin are expected to show strong growth, the former becoming the most valuable product for treating MRSA with almost blockbuster sales of US$911 million in 2016.
Of the new products expected to launch, Paratek Pharmaceuticals/Novartis’ PTK 0796 has an 80% chance of reaching the market, largely due to the drug’s advantageous mode of action and proof of concept and is forecast to achieve sales of US$454 million by 2016.
Squaring the circle?
The inherent commercial problems of developing an antibiotic which, by its nature, could be redundant in a short amount of time has not encouraged a great deal of the industry’s R&D spend to be invested in this area. However the spectre of ever mutating MRSA (and similar) pathogens leading to the uncontrolled spread of infection is possible. Pharma - and government - need to invest more in antibiotic R&D with the aim of developing drugs that work in new ways to attempt to avoid resistance development. In the US, the Infectious Diseases Society of America has suggested a number of incentives related to IP protection, tax breaks and funding to encourage industry to tackle more effectively this critical area.
This new 105+ page August 2010 report provides a complete briefing on MRSA and the companies, products and research that are shaping the sectors future More Information...
The benefits of this report:
- A comprehensive review of MRSA putting the pathogen into its research and clinical context
- Original analysis and 5-year sales forecasting for 11 launched and Phase III products
- An assessment of 5 promising Phase II pipeline prospects
- Novel, critical evaluation and scoring of each product
With this report you can...
- Understand the role of staphylococcus aureus
- Know the differing risk factors of HA-MRSA and CA-MRSA
- Know how MRSA manifests itself
- Understand how bacterial mutation occurs and resistance develops
- Evaluate trends in US prevalence of MRSA and assess which European countries have the highest/lowest incidence rates
- Understand the arguments around research funding and the incentives for the industry which are proposed in the US
- Review current product offerings: there are 8 products from 7 companies - what are they?
Questions answered...
- What development hurdles must Basilia overcome with Zeftera?
- What clinical advantages does Cubist’s Cubicin has over its competitors?
- To what degree will Pfizer’s Zyvox be affected by generic competition in 2015?
- What are the prospects and challenges for Forest’s new
Therapeutic approaches:
- Beta-lactum
- Glycopeptides
- Macrolides
- Streptogramins
- Aminoglycosides
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Renal Cell Carcinoma Cancer Drug Futures 2010
Product Profiles: Pipeline Antibacterials - Gram-negative combination antibiotics show promise in MRSA-focused pipeline
Pipeline Insight: Antibacterials
CNS Drug Discoveries: What the future holds 2008
New Drug Futures 2009
CNS Drug Discoveries: Multiple Sclerosis Chapter
Monoclonal Antibodies: what the future holds
The executive guide to Heat Shock Proteins
Obesity Drug Discoveries: what the future holds
CNS Drug Discoveries: Schizophrenia Chapter
|
|
|
|
